US20230278985A1 - Solid form of compound - Google Patents

Solid form of compound Download PDF

Info

Publication number
US20230278985A1
US20230278985A1 US18/019,747 US202118019747A US2023278985A1 US 20230278985 A1 US20230278985 A1 US 20230278985A1 US 202118019747 A US202118019747 A US 202118019747A US 2023278985 A1 US2023278985 A1 US 2023278985A1
Authority
US
United States
Prior art keywords
xrpd
degrees
ray powder
powder diffraction
including peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/019,747
Other languages
English (en)
Inventor
Zaiqi Wang
Jing Gao
Yingxia Sang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inxmed Nanjing Co Ltd
Inxmed Shanghai Co Ltd
Original Assignee
Inxmed Nanjing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inxmed Nanjing Co Ltd filed Critical Inxmed Nanjing Co Ltd
Publication of US20230278985A1 publication Critical patent/US20230278985A1/en
Assigned to INXMED (NANJING) CO., LTD. reassignment INXMED (NANJING) CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INXMED (SHANGHAI) CO., LTD.
Assigned to INXMED (SHANGHAI) CO., LTD. reassignment INXMED (SHANGHAI) CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GAO, JING, SANG, Yingxia, WANG, ZAIQI
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present disclosure belongs to the field of medicinal chemistry.
  • the present disclosure relates to a solid form of a compound.
  • FAK also known as protein tyrosine kinase 2 (PTK2), is a non-receptor tyrosine kinase and a key component of the focal adhesion complex.
  • PTK2 protein tyrosine kinase 2
  • FAK plays a critical role in mediating integrin and growth factor signaling to regulate tumor cell invasion, proliferation and survival.
  • FAK is widely expressed and evolutionarily conserved.
  • Studies in the past two decades have shown that FAK is overexpressed in a variety of solid tumors, and the expression level is negatively correlated with tumor prognosis. Recent studies have also shown that FAK plays an important role in regulating the tumor microenvironment, suggesting that FAK plays an important role in adaptive drug resistance of immunotherapy and anti-tumor therapy.
  • the compound of formula (I) is a FAK inhibitor, which exhibits anti-tumor activity in CDX (cell-line-derived xenograft) models of various tumors.
  • CDX cell-line-derived xenograft
  • the present disclosure provides a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof:
  • the salt is a pharmaceutically acceptable salt.
  • the solid form is a crystalline form.
  • the solid form is free base of the compound of formula (I).
  • the solid form is crystalline form A of the free base of the compound of formula (I).
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • it has an XRPD pattern substantially as shown in FIG. 1 .
  • it exhibits an endothermic event as characterized by DSC, with an onset temperature at about 212.95° C. and/or a peak temperature at about 214.24° C.
  • the solid form is crystalline form I of tartrate salt of formula (I).
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • it has an XRPD pattern substantially as shown in FIG. 3 .
  • it exhibits an endothermic event as characterized by DSC, with an onset temperature at about 235.42° C. and/or a peak temperature at about 235.89° C.
  • the solid form is crystalline form III of tartrate salt of formula (I).
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • it has an XRPD pattern substantially as shown in FIG. 5 .
  • it exhibits an endothermic event as characterized by DSC, with an onset temperature at about 235.42° C. and/or a peak temperature at about 235.89° C.
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • it has an XRPD pattern substantially as shown in FIG. 10 .
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • it has an XRPD pattern substantially as shown in FIG. 12 .
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • it has an XRPD pattern substantially as shown in FIG. 18 .
  • the present disclosure provides tartrate salt of a compound of formula (I),
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • it has an XRPD pattern substantially as shown in FIG. 3 .
  • the present disclosure provides a method for preparing a solid form of a compound of formula (I), comprising steps of:
  • the solvent is absolute ethanol.
  • the present disclosure provides a method for preparing a solid form of a salt of a compound of formula (I), comprising steps of:
  • the present disclosure provides a pharmaceutical composition, characterized in that the pharmaceutical composition comprises the solid form of the compound of formula (I) described in the present disclosure, in particular, an effective amount of the solid form of the compound of formula (I) described in the present disclosure, and a pharmaceutically acceptable excipient.
  • the present disclosure provides a use of the solid form of the compound of formula (I) or the pharmaceutical composition described in the present disclosure as a FAK inhibitor.
  • the present disclosure provides a use of the solid form of the compound of formula (I) or the pharmaceutical composition described in the present disclosure in the manufacture of a medicament for the treatment of Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, liver cancer, bile duct cancer, myelodysplastic syndrome, leukemia, thyroid cancer, glioma, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, sarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, thymus cancer, pancreatic cancer, uterine cancer, testicular cancer, melanoma, skin cancer, mesothelioma, thymoma, germinoma, glioblastoma, nasopharyngeal cancer, oropharyngeal cancer, or laryngeal cancer, or
  • FIG. 1 is the X-ray powder diffraction (XRPD) pattern of crystalline form A of free base of the compound of formula (I).
  • FIG. 2 a shows the thermogravimetry analysis (TGA) of crystalline form A of free base of the compound of formula (I);
  • FIG. 2 b shows the differential scanning calorimetry (DSC) analysis results of crystalline form A of free base of the compound of formula (I).
  • FIG. 3 is the X-ray powder diffraction (XRPD) pattern of crystalline form I of tartrate salt of the compound of formula (I).
  • FIG. 4 a shows the thermogravimetry analysis (TGA) of crystalline form I of tartrate salt of the compound of formula (I);
  • FIG. 4 b shows the differential scanning calorimetry (DSC) analysis results of crystalline form I of tartrate salt of the compound of formula (I);
  • FIG. 4 c shows the 1 H NMR (DMSO-d 6 ) of crystalline form I of tartrate salt of the compound of formula (I);
  • FIG. 4 d shows the dynamic vapor sorption (DVS) isotherm plot of crystalline form I of tartrate salt of the compound of formula (I).
  • FIG. 5 is the X-ray powder diffraction (XRPD) pattern of crystalline form III of tartrate salt of the compound of formula (I).
  • FIG. 5 a shows the thermogravimetry analysis (TGA) of crystalline form III of tartrate salt of the compound of formula (I);
  • FIG. 5 b shows the differential scanning calorimetry (DSC) analysis results of crystalline form III of tartrate salt of the compound of formula (I);
  • FIG. 5 c shows the 1 H NMR (DMSO-d 6 ) of crystalline form III of tartrate salt of the compound of formula (I);
  • FIG. 5 d shows the dynamic vapor sorption (DVS) isotherm plot of crystalline form III of tartrate salt of the compound of formula (I).
  • FIG. 6 shows the XRPD pattern of crystalline form B of free base of the compound of formula (I).
  • FIG. 7 shows the XRPD pattern of crystalline form C of free base of the compound of formula (I).
  • FIG. 8 shows the XRPD pattern of crystalline form D of free base of the compound of formula (I).
  • FIG. 9 shows the XRPD pattern of crystalline form I of sulfate salt of the compound of formula (I).
  • FIG. 10 shows the XRPD pattern of crystalline form I of phosphate salt of the compound of formula (I).
  • FIG. 11 shows the XRPD pattern of crystalline form II of phosphate salt of the compound of formula (I).
  • FIG. 12 shows the XRPD pattern of crystalline form I of maleate salt of the compound of formula (I).
  • FIG. 13 shows the XRPD pattern of crystalline form II of maleate salt of the compound of formula (I).
  • FIG. 14 shows the XRPD pattern of crystalline form I of citrate salt of the compound of formula (I).
  • FIG. 15 shows the XRPD pattern of crystalline form I of lactate salt of the compound of formula (I).
  • FIG. 16 shows the XRPD pattern of crystalline form I of benzenesulfonate salt of the compound of formula (I).
  • FIG. 17 shows the XRPD pattern of crystalline form I of 2-hydroxyethanesulfonate salt of the compound of formula (I).
  • FIG. 18 shows the XRPD pattern of crystalline form I of benzoate salt of the compound of formula (I).
  • FIG. 19 shows the XRPD pattern of crystalline form I of p-toluenesulfonate salt of the compound of formula (I).
  • FIG. 20 shows the XRPD pattern of crystalline form I of hydrobromide salt of the compound of formula (I).
  • FIG. 21 is the stability analysis of crystalline form A of the free base.
  • FIG. 22 is the stability analysis of crystalline form I of the tartrate salt.
  • FIG. 23 is the stability analysis of crystalline form III of the tartrate salt.
  • FIG. 24 is the XRPD pattern for the stress stability of crystalline form A of the free base.
  • FIG. 25 is the XRPD pattern for the stress stability of crystalline form I of the tartrate salt.
  • FIG. 26 is the XRPD pattern for the stress stability of crystalline form III of the tartrate salt.
  • FIG. 27 is the XRPD pattern for the grinding stability of crystalline form A of the free base.
  • FIG. 28 is the XRPD pattern for the grinding stability of crystalline form I of the tartrate salt.
  • FIG. 29 is the XRPD pattern for the grinding stability of crystalline form III of the tartrate salt.
  • FIG. 30 is the analysis of the suspension competition assay of tartrate salt I and tartrate salt III at room temperature.
  • FIG. 31 is the analysis of the suspension competition assay of tartrate salt I and tartrate salt III at 50° C.
  • the term “about” or “approximately” when used in combination with a value or range of values means that it may deviate from the described value or range of values by a reasonable range considered by those skilled in the art, for example within experimental variation (or within statistics experimental error), so it may vary, for example, between 1% and 15%, between 1% and 10%, between 1% and 5%, between 0.5% and 5%, or between 0.5% and 1% of the described value or range of values.
  • the situation where a value or range of values is preceded by the term “about” also includes an embodiment of the given value.
  • “about 3° C.” discloses an embodiment where the temperature is “3° C.”
  • the terms “about” and “approximately” are used entirely interchangeably.
  • the term “between” includes endpoint numbers at both ends of the range limit.
  • “between 3 and 5” describes a range that includes the numbers “3” and “5.”
  • a wave line i.e., “ ⁇ ” preceding a value or range of values means “about” or “approximately.”
  • mixing refers to forming a mixture of one or more chemical entities with another chemical entity or entities.
  • Mixing includes the process of adding one or more compounds to a solid, liquid or gas mixture, or liquid solution, or multiphase liquid mixture of one or more compounds (the same or other chemical entities), e.g., bond formation or cleavage; salt formation, solvate formation, chelation, or other association that changes non-bonds.
  • the effect of mixing may involve altering one or more compounds, such as by isomerization (e.g., interconversion, resolution of one isomer from another, or racemization).
  • pharmaceutically acceptable means non-toxic, biologically tolerable, and suitable for administration to a subject.
  • the term “pharmaceutically acceptable salt” refers to a non-toxic, biologically tolerable salt suitable for administration to a subject.
  • a pharmaceutically acceptable salt of the compound refers to a non-toxic, biologically tolerable acid addition salt suitable for administration to a subject, including but not limited to: acid addition salts of said compound with an inorganic acid such as hydrochloride, hydrobromide, carbonate, bicarbonate, phosphate, sulfate, sulfite, nitrate, etc.; and acid addition salts of said compound with an organic acids, such as formate, acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, mesylate, p-toluenesulfonate, 2-hydroxyethanesulfonate, benzoate, salicylate, stearate and salts with an alkanedicarboxylic acid of formula HOOC—(CH 2 ) n —COOH (wherein n
  • the free base can be obtained by basifying a solution of the salt.
  • a pharmaceutically acceptable salt can be prepared by dissolving the free base in a suitable organic solvent and treating the solution with an acid by conventional methods of preparing acid addition salts from free base compounds.
  • the salt is tartrate, hydrochloride, succinate, salicylate or fumarate.
  • the salt is tartrate.
  • solvate refers to a compound that further includes a stoichiometric or non-stoichiometric solvent bound by a non-covalent intermolecular force.
  • a solvate is a “hydrate” when the solvent is water.
  • a solvate may be a channel solvate. It should be understood that the term “solvate” as used herein includes a compound and a solvate of a compound, as well as a mixture thereof.
  • solvent refers to an organic solvent that is inert under the described reaction condition, including but not limited to benzene, toluene, acetonitrile (MeCN), ethyl acetate (EtOAc), isopropyl acetate (IPAc), hexane, heptane, dioxane, tetrahydrofuran (THF), dimethylformamide (DMF), chloroform, dichloromethane (DCM), diethyl ether, methanol (MeOH), ethanol, isopropanol, butanol, methyl tert-butyl ether (MTBE or TBME), dioxane, acetone, 2-butanone (MEK), N-methylpyrrolidone (NMP), pyridine, etc.
  • solvent organic solvent that is inert under the described reaction condition, including but not limited to benzene, toluene, acetonitrile (MeCN), ethy
  • solvent examples include but are not limited to ethyl acetate (EtOAc), tetrahydrofuran (THF), methanol (MeOH), 75% ethanol, dioxane, methyl tert-butyl ether, acetone, and the like.
  • EtOAc ethyl acetate
  • MeOH methanol
  • 75% ethanol dioxane, methyl tert-butyl ether, acetone, and the like.
  • the solvents used in the reactions described herein are inert organic solvents.
  • subject refers to both mammals and non-mammals.
  • Mammal means any member of the class Mammalia, which includes, but is not limited to: humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats and pigs; domestic animals such as rabbits, dogs and cats; laboratory animals including rodents such as rats, mice and guinea pigs; etc.
  • non-mammals include, but are not limited to, birds and the like.
  • the term “subject” is not limited to a specific age or gender. In some embodiments, the subject is a human.
  • treating refers to obtaining a desired pharmacological and/or physiological effect.
  • the effect may be therapeutic, including partial or substantial achievement of one or more of the following results: partial or total alleviation of the extent of the disease, condition or syndrome; improvement of clinical symptoms or indicators associated with the disease; or delay, suppression or reduction of likelihood of disease, condition or syndrome progression.
  • an effective amount refers to a solid form of the compound of formula (I) sufficient to reduce or ameliorate the severity, duration, progression or onset of a disease or condition, delay or arrest the progression of a disease or condition, cause the regression of a disease or condition, or delay the recurrence or progression of a symptom, or enhance or improve the therapeutic effect of another therapy.
  • the precise amount administered to a subject will depend on various factors, such as the given drug or compound, pharmaceutical formulation, route of administration, type of disease, condition, identity of the subject or host being treated, etc., and can still be routinely determined by those skilled in the art. For example, determining an effective amount also depends on the degree, severity and type of cell proliferation.
  • the “effective amount” of any other therapeutic agent will depend on the type of drug used. Appropriate dosages are known for approved therapeutic agents and can be adjusted by a skilled artisan according to the condition of the subject, the type of condition being treated, and the amount of the compound or a pharmaceutically acceptable salt thereof. Where no amount is expressly stated, some amount should be assumed.
  • the effective amount of a solid form of the compound of formula (I) may be 10 ⁇ g to 2000 mg. This example is non-limiting.
  • Solid forms of the compounds of formula (I) may be administered by any suitable method of administration. Suitable methods include oral, intravenous, intramuscular or subcutaneous administration to a subject.
  • pharmaceutically acceptable excipient or “pharmaceutically acceptable carrier” as used herein includes any and all solvents, dispersion media, coatings, antibacterial agents, isotonic agents, absorption delaying agents and the like. Using such media and agents for pharmaceutically active substances is well known to those skilled in the art. Unless any conventional media or agents are incompatible with the active ingredients, they are contemplated for being used in the composition herein. Supplementary active ingredients can also be incorporated into the pharmaceutical composition.
  • a solid form of the compound of formula (I) can be administered orally together with a pharmaceutically acceptable carrier such as an inert diluent or an absorbable edible carrier. They can be enclosed in hard or soft shell gelatin capsules, can be compressed into tablets, or can be mixed directly with the patient's food.
  • a pharmaceutically acceptable carrier such as an inert diluent or an absorbable edible carrier.
  • the compound or a pharmaceutically acceptable salt thereof may be combined with one or more excipients, and used as ingestible tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups or wafers, etc. These formulations contain an effective amount of the compound of formula (I) (or a pharmaceutically acceptable salt thereof).
  • Tablets, lozenges, pills, capsules, etc. may further include: binders such as tragacanth, acacia, cornstarch or gelatin; excipients such as dicalcium phosphate; disintegrants such as cornstarch, potato starch, alginic acid, etc.; lubricants, such as magnesium stearate; or sweeteners, such as sucrose, fructose, lactose or aspartame; or flavoring agents.
  • binders such as tragacanth, acacia, cornstarch or gelatin
  • excipients such as dicalcium phosphate
  • disintegrants such as cornstarch, potato starch, alginic acid, etc.
  • lubricants such as magnesium stearate
  • sweeteners such as sucrose, fructose, lactose or aspartame; or flavoring agents.
  • a solid form of the compound of formula (I) can also be administered intravenously or intraperitoneally by infusion or injection.
  • Exemplary pharmaceutical dosage forms for injection or infusion include: sterile aqueous solutions, dispersions, or sterile powders containing an active ingredient which are suitable for the extemporaneous preparation of sterile injection or infusion solutions or dispersions.
  • the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
  • the sterile injection solution can be prepared by mixing a required amount of the solid form of the compound (XRPD pattern for the grinding stability of crystalline form I of the tartrate salt in FIG. 13 ) in an appropriate solvent with the required above-mentioned other ingredients, and then being sterilized by filteration.
  • the preferred methods of preparation may be vacuum drying and freeze-drying technique which can yield a powder of the active ingredient plus any other desired ingredient present after previous sterile filtration.
  • the amount of solid form of the compound of formula (I) required for treatment may vary not only with the particular salt chosen, but also with the route of administration, the nature of the disease to be treated and the age and condition of the patient, and ultimately can be at the discretion of the attending physician or clinician. In general, however, dosages may range from about 0.1 to about 50 mg/kg body weight per day.
  • the required dose may conveniently be presented in a single dose or in divided doses administered at appropriate intervals.
  • solid form and related terms refer to physical forms that are not primarily liquid or gaseous. Solid forms may be crystalline, amorphous or a mixture thereof.
  • crystalline form refers to a crystal form. It includes single component crystalline form and multicomponent crystalline form, and includes, but is not limited to, polymorphs, solvates, and other molecular complexes, as well as salts thereof, solvates of salts, other molecular complexes of salts, and polymorphs of salts.
  • a crystalline form of a substance may be substantially free of amorphous forms and/or other crystalline forms.
  • a crystalline form of a substance may contain less than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% by weight of one or more amorphous forms and/or other crystalline forms.
  • a crystalline form of a substance may be physically and/or chemically pure.
  • a crystalline form of a substance may be about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% physically and/or chemically pure.
  • the crystalline form described herein is substantially pure, i.e., substantially free of other crystalline forms and/or other compounds, containing less than about 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.75%, 0.5%, 0.25% or 0.1% by weight of one or more other crystalline forms and/or other compounds.
  • Crystalline forms can exhibit different physical characteristic data that are unique to a particular crystalline form, such as the crystalline forms described herein. These characteristic data can be obtained by various techniques known to those skilled in the art, including, for example, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and nuclear magnetic resonance spectroscopy (HNMR). The data provided by these techniques can be used to identify specific crystalline forms. Those skilled in the art can determine whether a crystalline form “matches” the reference data provided herein that are identified as being specific to a particular crystalline form. Characteristic data that “match” the data of the reference crystalline form is understood by those skilled in the art to correspond to the same crystalline form as the reference crystalline form. In the analysis of whether the data “match” or not, those skilled in the art will understand that, due to for example experimental error and routine sample-to-sample analysis, specific characteristic data points may vary to a reasonable extent and still describe a given crystalline form.
  • Amorphous or “amorphous form” and related terms as used herein mean that the substance, component or product is not substantially crystalline as determined by X-ray powder diffraction.
  • the term “amorphous” describes a disordered solid form, i.e., a solid form that lacks a long-range crystal order.
  • an amorphous form of a substance may be substantially free of other amorphous forms and/or crystalline forms.
  • the amorphous form of a substance may contain less than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% by weight of one or more other amorphous forms and/or crystalline forms.
  • an amorphous form of a substance may be physically and/or chemically pure.
  • an amorphous form of a substance may be about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% physically and/or chemically pure.
  • the present disclosure provides a solid form comprising a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof:
  • a solid form comprising the compound of formula (I) may be a crystalline form, a partially crystalline form, or a mixture of crystalline and amorphous forms.
  • the solid form may comprise a crystalline form of the compound of formula (I), or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.
  • the solid form further comprises a co-former.
  • a co-crystal of the compound of formula (I) and the co-former in a solid form is included.
  • the solid form is amorphous. In some embodiments, the solid form is substantially pure.
  • the solid form comprises a solid form of the free base of the compound of formula (I) or a solvate thereof. In some embodiments, the solid form comprises a solid form of the anhydrous free base of the compound of formula (I). In some embodiments, the solid form comprises a solid form of a solvate of the free base of the compound of formula (I).
  • the compound of formula (I), or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof may exist in various solid forms. Such solid forms include crystalline forms, amorphous solids, or mixtures of crystalline and amorphous forms. In some embodiments, the solid form is substantially a crystalline form. In some embodiments, the solid form is a crystalline form.
  • the molar ratio of the compound of formula (I) to solvent/water in the solid form ranges from about 10:1 to about 1:10. In some embodiments, the molar ratio of the compound of formula (I) to solvent/water in the solid form ranges from about 5:1 to about 1:5. The molar ratio of the compound of formula (I) to solvent/water in the solid form ranges from about 3:1 to about 1:3. The molar ratio of the compound of formula (I) to solvent/water in the solid form ranges from about 2:1 to about 1:2. In some embodiments, the molar ratio is about 1:2 (i.e., disolvate). In some embodiments, the molar ratio is about 1:1 (i.e., monosolvate). In some embodiments, the molar ratio is about 2:1 (i.e., hemisolvate).
  • the solid form is crystalline form A of free base of the compound of formula (I). In some embodiments, crystalline form A of the free base is substantially free of amorphous forms. In some embodiments, crystalline form A of the free base is substantially free of other crystalline forms. In some embodiments, crystalline form A of the free base is substantially free of salts of the compound of formula (I). In some embodiments, crystalline form A of the free base is substantially pure crystalline form A.
  • crystalline form A of the free base has X-ray powder diffraction (XRPD) including peaks at 4.8, 9.6, 11.0, 11.5, 17.4, 19.3, 21.6, 22.3, 22.5, and 24.8 degrees 2 ⁇ .
  • crystalline form A of the free base has an XRPD pattern substantially as shown in FIG. 1 .
  • crystalline form A of the free base exhibits a weight loss of about 0.46% when heated from about 25° C. to about 172° C.
  • crystalline form A of the free base has a TGA spectrum substantially as shown in FIG. 2 a . From TGA analysis, crystalline form A of free base of the compound of formula (I) is a non-solvate.
  • crystalline form A of the free base exhibits an endothermic event as characterized by DSC, with an onset temperature at about 212.95° C. and/or a peak temperature at about 214.24° C.
  • crystalline form A of the free base has a DSC spectrum substantially as shown in FIG. 2 b.
  • the solid form is a salt of the compound of formula (I).
  • the compound of formula (I) forms a salt with an acid.
  • the ratio of the compound of formula (I) to an acid may be stoichiometric or non-stoichiometric. In some embodiments, the ratio of the compound of formula (I) to the acid ranges from about 5:1 to about 1:5. In some embodiments, the ratio of the compound of formula (I) to the acid ranges from about 5:1, 4:1, 3:1, 2.5:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:4, or 1:5. In some embodiments, the ratio of the compound of formula (I) to the acid is about 1:1.
  • the acid is one or more of tartaric acid, hydrochloric acid, succinic acid, salicylic acid, sulfuric acid, phosphoric acid, acetic acid, maleic acid, fumaric acid, citric acid, malic acid, lactic acid, gluconic acid, aspartic acid, hippuric acid, glutamic acid, adipic acid, methanesulfonic acid, benzenesulfonic acid, benzoic acid, 2-hydroxyethanesulfonic acid, p-toluenesulfonic acid, 2-naphthalenesulfonic acid and hydrobromic acid.
  • the acid is one or more of tartaric acid, hydrochloric acid, succinic acid, salicylic acid, and fumaric acid.
  • the solid form is the crystalline form of tartrate salt of the compound of formula (I). In some embodiments, the solid form is crystalline form I of tartrate salt of the compound of formula (I). In crystalline form I of tartrate salt of the compound of formula (I), the molar ratio of the compound of formula (I) to tartaric acid is about 1:1. In some embodiments, it has X-ray powder diffraction (XRPD) including peaks at 10.3, 13.0, 18.0, 18.3, 21.2, 21.9, 23.1, 25.7, 27.3, and 30.0 degrees 2 ⁇ . In some embodiments, it has an XRPD pattern substantially as shown in FIG. 3 .
  • XRPD X-ray powder diffraction
  • crystalline form I of tartrate salt of the compound of formula (I) exhibits a weight loss of about 0.87% when heated from about 25° C. to about 158° C. In some embodiments, it has a TGA spectrum substantially as shown in FIG. 4 a . From TGA analysis, crystalline form I of tartrate salt of the compound of formula (I) is a non-solvate.
  • crystalline form I of tartrate salt of the compound of formula (I) exhibits an endothermic event as characterized by DSC, with an onset temperature at about 235.42° C. and/or a peak temperature at about 235.89° C. In some embodiments, it has a DSC spectrum substantially as shown in FIG. 4 b.
  • crystalline form I of tartrate salt of the compound of formula (I) exhibits a weight gain of about 1% when subjected to an increase in relative humidity from about 0 to about 95% relative humidity. In some embodiments, it has a DVS spectrum substantially as shown in FIG. 4 c.
  • the present disclosure provides a pharmaceutical combination, characterized in that the pharmaceutical combination comprises the solid form of the compound of formula (I), in particular, an effective amount of the solid form of the compound of formula (I), and a pharmaceutically acceptable excipient.
  • the present disclosure provides a use of the solid form of the compound of formula (I) and the pharmaceutical composition described in the present disclosure in the manufacture of a medicament for the treatment of the following diseases: Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, liver cancer, bile duct cancer, myelodysplastic syndrome, leukemia, thyroid cancer, glioma, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, sarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, thymus cancer, pancreatic cancer, uterine cancer, testicular cancer, melanoma, skin cancer, mesothelioma, thymoma, germinoma, glioblastoma, nasopharyngeal cancer, oropharyngeal cancer, or
  • crystalline form A of the free base is the most preferred crystalline form of the free base of the compound of formula (I).
  • the free base (1.7 g) obtained as described above was dissolved in absolute ethanol (170 mL), and stirred at 82-87° C. for 1-2 hours. The solution was cooled to room temperature, and distilled under reduced pressure to remove part of the solvent until a solid was precipitated out. The mixture was then left to stand. The solid was collected and dried to obtain crystalline form A of the free base.
  • Crystalline form A of the free base (17.6 mg, about 0.03 mmol) was added to a 10 mL sample bottle, and an appropriate amount of reaction solvent was added. The mixture was dissolved by stirring, and then acid solutions (at a reaction molar ratio of 1:1) were added, respectively. The mixture was reacted at 50° C. for 3 h. The reaction solution was then cooled to room temperature, further stirred overnight, and then placed in a refrigerator at 4° C. to stand for 8 h. The samples without solid precipitation were volatilized at room temperature to obtain a solid, which was then measured by XRPD. The samples with solid precipitation were centrifuged to remove the solvent. The solid obtained by centrifugation and the solid obtained by volatilization of the supernatant were dried separately and then subjected to XRPD measurement to determine whether a salt was formed. The results are shown in Table 2.
  • the I or II mentioned in the above table are different crystalline forms of the respective acids after the corresponding acid radicals are salified.
  • the acid is sulfuric acid and the solvent is ethyl acetate
  • crystalline form I obtained by precipitation is crystalline form I of the sulfate salt, and so on for other crystalline forms.
  • the A, B and C are all crystalline forms of the free base of the compound. NA means no sample was acquired.
  • FIG. 6 shows the XRPD pattern of crystalline form B of free base of the compound of formula (I).
  • FIG. 7 shows the XRPD pattern of crystalline form C of free base of the compound of formula (I).
  • FIG. 8 shows the XRPD pattern of crystalline form D of free base of the compound of formula (I).
  • FIG. 9 shows the XRPD pattern of crystalline form I of sulfate salt of the compound of formula (I).
  • FIG. 10 shows the XRPD pattern of crystalline form I of phosphate salt of the compound of formula (I).
  • FIG. 11 shows the XRPD pattern of crystalline form II of phosphate salt of the compound of formula (I).
  • FIG. 12 shows the XRPD pattern of crystalline form I of maleate salt of the compound of formula (I).
  • FIG. 13 shows the XRPD pattern of crystalline form II of maleate salt of the compound of formula (I).
  • FIG. 14 shows the XRPD pattern of crystalline form I of citrate salt of the compound of formula (I).
  • FIG. 15 shows the XRPD pattern of crystalline form I of lactate salt of the compound of formula (I).
  • FIG. 16 shows the XRPD pattern of crystalline form I of benzenesulfonate salt of the compound of formula (I).
  • FIG. 17 shows the XRPD pattern of crystalline form I of 2-hydroxyethanesulfonate salt of the compound of formula (I).
  • FIG. 18 shows the XRPD pattern of crystalline form I of benzoate salt of the compound of formula (I).
  • FIG. 19 shows the XRPD pattern of crystalline form I of p-toluenesulfonate salt of the compound of formula (I).
  • FIG. 20 shows the XRPD pattern of crystalline form I of hydrobromide salt of the compound of formula (I).
  • a certain amount of crystalline form A of free base of the compound of formula (I), crystalline form I of the tartrate salt, and crystalline form III of the tartrate salt were weighed and placed in a 5 mL sample bottle.
  • Deionized water, pH 2.0 glycine-hydrochloric acid buffer solution, pH 4.5 Na 2 HPO 4 -citric acid buffer solution, and pH 6.8 Na 2 HPO 4 -citric acid buffer solution were added respectively (each 2 mL).
  • the mixture was placed on a shaker at 25° C., shaken for 24 hours, and then filtered.
  • the filtrate was tested for solubility by HPLC; and the solid was detected by XRPD to determine whether the crystalline form was transformed.
  • the results of the solubility test show that compared with the amorphous form of the free base, the solubility of crystalline form A of the free base in pH 6.8 buffered saline solution is significantly improved.
  • the solubility of crystalline form I of the tartrate salt is significantly improved in both deionized water and pH 6.8 buffered saline solution.
  • Crystalline form III of the tartrate salt has very good solubility in all the solvent systems.
  • the increased solubility in deionized water greatly reduces formulation difficulty; and the increased solubility in pH 6.8 buffered saline solution greatly increases the oral bioavailability of the drug.
  • As detected by XRPD no crystal transformation occurs for crystalline form A of the free base in pH 6.8 buffered saline solution and deionized water; and no crystal transformation occurs for crystalline form I of the tartrate salt in deionized water.
  • High temperature test The powder was placed in a suitable sealed glass bottle, and placed at 60° C. for 10 days. Samples were taken on the 5th and 10th day to detect the solid XRPD.
  • High humidity test The powder was placed in an open constant temperature and humidity box, and placed at 25° C., 90% ⁇ 5% RH for 10 days. Samples were taken on the 5th and 10th day and the solid XRPD was detected so as to investigate the moisture absorption and deliquescence performances.
  • Strong light irradiation test (L) The powder was placed in an open box equipped with a fluorescent lamp, and placed under the condition of an illumination of 4500 ⁇ 500 lx for 10 days. Samples were taken on the 5th and 10th day to detect the solid XRPD.
  • Dynamic water adsorption instrument (DVS) was used to investigate the adsorption and desorption test of crystalline forms I and III of the tartrate salt at 25° C. in the range of 0-95% relative humidity, so as to determine hygroscopicity of various crystalline forms (For details, see FIGS. 4 d and 5 d ).
  • the results show that in the humidity range of 40-80% RH, the moisture absorption of crystalline form I is 0.33%, and the moisture absorption of crystalline form III is 0.37%.
  • Crystalline form I is significantly more stable than crystalline form III under high humidity conditions (RH >90%). Crystalline form III has a moisture absorption of 18.1% from 90% to 95% RH, while crystalline form I of the tartrate salt has almost no moisture absorption (0.08%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
US18/019,747 2020-08-03 2021-08-02 Solid form of compound Pending US20230278985A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010768730 2020-08-03
CN202010768730.1 2020-08-03
CN202010837005.5 2020-08-19
CN202010837005 2020-08-19
PCT/CN2021/110069 WO2022028367A1 (zh) 2020-08-03 2021-08-02 化合物的固体形式

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/110069 A-371-Of-International WO2022028367A1 (zh) 2020-08-03 2021-08-02 化合物的固体形式

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/347,335 Continuation US11999719B2 (en) 2020-08-03 2023-07-05 Solid form of compound

Publications (1)

Publication Number Publication Date
US20230278985A1 true US20230278985A1 (en) 2023-09-07

Family

ID=80119956

Family Applications (2)

Application Number Title Priority Date Filing Date
US18/019,747 Pending US20230278985A1 (en) 2020-08-03 2021-08-02 Solid form of compound
US18/347,335 Active US11999719B2 (en) 2020-08-03 2023-07-05 Solid form of compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/347,335 Active US11999719B2 (en) 2020-08-03 2023-07-05 Solid form of compound

Country Status (13)

Country Link
US (2) US20230278985A1 (ja)
EP (1) EP4190774A4 (ja)
JP (1) JP2023536491A (ja)
KR (1) KR20230048089A (ja)
CN (1) CN116096713A (ja)
AU (1) AU2021323235A1 (ja)
BR (1) BR112023001962A2 (ja)
CA (1) CA3188244A1 (ja)
CL (1) CL2023000313A1 (ja)
MX (1) MX2023001418A (ja)
PE (1) PE20231303A1 (ja)
TW (1) TW202206425A (ja)
WO (1) WO2022028367A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023160614A1 (zh) * 2022-02-28 2023-08-31 微境生物医药科技(上海)有限公司 作为fak抑制剂的化合物及其用途
TW202408528A (zh) * 2022-06-24 2024-03-01 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AU2020245902A1 (en) * 2019-03-28 2021-09-30 Amplia Therapeutics Limited A salt and crystal form of a FAK inhibitor
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
AU2020388848A1 (en) * 2019-11-18 2022-05-26 Inxmed (Nanjing) Co., Ltd. Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
WO2021104454A1 (zh) * 2019-11-28 2021-06-03 应世生物科技(南京)有限公司 Bi853520在癌症治疗中的用途
KR20230011908A (ko) * 2020-01-31 2023-01-25 베라스템, 인코포레이티드 비정상적 세포 성장을 치료하기 위한 조합 요법
MX2022009612A (es) * 2020-02-05 2022-09-19 Inxmed Nanjing Co Ltd Combinacion de bi853520 con farmacos quimioterapeuticos.

Also Published As

Publication number Publication date
PE20231303A1 (es) 2023-08-24
CN116096713A (zh) 2023-05-09
CA3188244A1 (en) 2022-02-10
CL2023000313A1 (es) 2023-07-28
EP4190774A4 (en) 2024-01-17
TW202206425A (zh) 2022-02-16
US20240051942A1 (en) 2024-02-15
JP2023536491A (ja) 2023-08-25
AU2021323235A1 (en) 2023-03-02
US11999719B2 (en) 2024-06-04
BR112023001962A2 (pt) 2023-04-11
MX2023001418A (es) 2023-04-10
WO2022028367A1 (zh) 2022-02-10
KR20230048089A (ko) 2023-04-10
EP4190774A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US11999719B2 (en) Solid form of compound
RU2497820C2 (ru) Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1 - н-бензимидазол-2-ил]хинолин-2(1н)она
ES2968174T3 (es) Forma en estado sólido de succinato de ribociclib
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
US8946249B2 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
CN112010839B (zh) 靶向丝/苏氨酸激酶抑制剂的晶型
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
US10640487B2 (en) Solid state forms of Nilotinib salts
KR102466958B1 (ko) 단백질 키나제 활성을 억제하는 화합물의 결정 형태 및 이의 응용
WO2013181251A9 (en) Crizotinib hydrochloride salt in crystalline
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
WO2024120441A1 (zh) 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2023230968A1 (zh) Shp2抑制剂、其晶型及其制备方法与用途
CN111825689B (zh) 一种二氢吡唑啉酮类化合物的晶型及其制备方法
US20230064976A1 (en) Amorphous form or crystalline form of 2-indolinolinololylspironone compounds or their salts, solvent complexes
KR20200006078A (ko) 화합물의 염 및 그것의 결정 형태
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
WO2023242809A1 (en) Crystalline forms of 4-[(5-chloropyridin-2-yl)methoxy]-1-[3-(propan-2-yl)-1h,2h,3h,4h,5h-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one and salts thereof, method of preparation, and uses thereof
CA3239187A1 (en) Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof
CN117209500A (zh) Shp2抑制剂、其晶型及其制备方法与用途
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
WO2016101912A1 (zh) 一种表皮生长因子受体激酶抑制剂的盐的晶型及其制备方法
EP2491027A1 (en) Salts of imatinib with tartaric acids

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: INXMED (NANJING) CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INXMED (SHANGHAI) CO., LTD.;REEL/FRAME:066572/0210

Effective date: 20230109

Owner name: INXMED (SHANGHAI) CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, ZAIQI;GAO, JING;SANG, YINGXIA;REEL/FRAME:066453/0731

Effective date: 20230109